Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

GRK5 is an Essential Co-repressor for Cardiac Mineralocorticoid Receptor Antagonism induced by Finerenone but not Eplerenone

Version 1 : Received: 16 September 2020 / Approved: 17 September 2020 / Online: 17 September 2020 (05:24:29 CEST)

How to cite: Desimine, V.L.; Ghandour, J.; Cora, N.; Pollard, C.M.; Valiente, R.; Ferraino, K.E.; Pereyra, J.; Pi Noa, D.; Duarte, Y.; Martinez, Y.; Maning, J.; Parker, B.M.; Brill, A.R.; Guidi, V.; Aukszi, B.; Lymperopoulos, A. GRK5 is an Essential Co-repressor for Cardiac Mineralocorticoid Receptor Antagonism induced by Finerenone but not Eplerenone. Preprints 2020, 2020090374 (doi: 10.20944/preprints202009.0374.v1). Desimine, V.L.; Ghandour, J.; Cora, N.; Pollard, C.M.; Valiente, R.; Ferraino, K.E.; Pereyra, J.; Pi Noa, D.; Duarte, Y.; Martinez, Y.; Maning, J.; Parker, B.M.; Brill, A.R.; Guidi, V.; Aukszi, B.; Lymperopoulos, A. GRK5 is an Essential Co-repressor for Cardiac Mineralocorticoid Receptor Antagonism induced by Finerenone but not Eplerenone. Preprints 2020, 2020090374 (doi: 10.20944/preprints202009.0374.v1).

Abstract

Background: In the heart, aldosterone (Aldo) binds the mineralocorticoid receptor (MR) to exert damaging, adverse remodeling-promoting effects. We recently showed that G protein-coupled receptor (GPCR)-kinase (GRK)-5 blocks the cardiac MR by directly phosphorylating it, thereby repressing its transcriptional activity. MR antagonist (MRA) drugs block the cardiac MR reducing morbidity and mortality of advanced human heart failure. Non-steroidal MRAs, such as finerenone, may provide better cardio-protection against Aldo than classic, steroidal MRAs, like spironolactone and eplerenone. Herein, we sought to investigate potential differences between finerenone and eplerenone at engaging GRK5-dependent cardiac MR phosphorylation and subsequent blockade. Methods: We used the cardiomyocyte cell line H9c2 and neonatal rat ventricular myocytes (NRVMs). Results: GRK5 phosphorylates the MR in H9c2 cardiomyocytes in response to finerenone but not to eplerenone. Unlike eplerenone, finerenone alone potently and efficiently suppresses cardiac MR transcriptional activity, thus displaying inverse agonism. GRK5 is necessary for finerenone`s inverse agonism, since GRK5 genetic deletion renders finerenone incapable of blocking cardiac MR transcriptional activity. Eplerenone alone does not fully suppress cardiac MR basal activity regardless of GRK5 expression levels. Finally in NRVMs, GRK5 is necessary for the anti-apoptotic and anti-fibrotic effects of both finerenone and eplerenone against Aldo, as well as for the higher efficacy and potency of finerenone at blocking Aldo-induced apoptosis and fibrosis. Conclusions: Finerenone, but not eplerenone, induces GRK5-dependent cardiac MR inhibition, which underlies, at least in part, its higher potency and efficacy, compared to eplerenone, as an MRA in the heart. GRK5 acts as a co-repressor of the cardiac MR and is essential for efficient MR antagonism in the myocardium.

Subject Areas

aldosterone; apoptosis; cardiac myocyte; eplerenone; fibrosis; finerenone; G protein-coupled receptor kinase (GRK)-5; mineralocorticoid receptor; mineralocorticoid receptor antagonist (MRA); signal transduction

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.